Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition
HONG KONG, Nov. 20, 2025 /PRNewswire/ -- On 19 November, the 7th "ESG Leading Enterprises 2025" ceremony, co-organized by Bloomberg Businessweek/Chinese Edition and Deloitte, a globally renowned accounting firm, was successfully held in Hong Kong....
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has...
Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
HONG KONG, Nov. 7, 2025 /PRNewswire/ -- On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted "The Asset Corporate Sustainability Leadership Awards 2025" ceremony in Singapore. Fosun International Limited ("Fosun...
Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- On 16 October, the 2025 Sustainability Global Leaders Conference was held in Shanghai. Themed "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth", the Conference brought...
Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review
HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review, that it has received three awards: "ESG &...
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the...
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2024 Annual Results Highlights: Total revenue reached RMB192.14 billion; Industrial operation profit amounted to RMB4.9 billion; Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's...
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached...
Guo Guangchang: Fosun Emphasizes Strategic Advancement and Exits, Focuses on Core Businesses, and Leverages Operational Capabilities to Participate in Global Markets
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- On 21 February, Guo Guangchang, Chairman of Fosun International spoke at the 25th Annual Conference of Yabuli China Entrepreneurs Forum 2025, stating that private enterprises are not afraid of competition as...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC Serplulimab has now...